Clinical Trials on Mucopolysaccharidosis Type I (MPS I) in Canada

Total 187 results

Genzyme, a Sanofi Company

Recruiting

Mucopolysaccharidosis I (MPS I) Registry

Mucopolysaccharidosis I (MPS I)

Croatia, United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, France, Hong Kong, India, Indonesia, Korea, Republic of, Kuwait, Lebanon, Malaysia, Netherlands, Pakistan, Philippines, Poland, Saudi Arabia, Singapore, Slovaki... and more
Children's Hospital of Eastern Ontario

Completed

Ultrasound Findings of Finger, Wrist and Knee Joints in Mucopolysaccharidosis

MPS I | MPS IV

Canada
University of Minnesota
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Completed

Longitudinal Studies of Brain Structure and Function in MPS Disorders

Mucopolysaccharidosis Type I | Mucopolysaccharidosis Type II | Mucopolysaccharidosis Type VI | Mucopolysaccharidosis Type IV | Mucopolysaccharidosis Type VII

United States, Canada
REGENXBIO Inc.

Active, not recruiting

RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)

Mucopolysaccharidosis Type II (MPS II)

United States, Canada
Genzyme, a Sanofi Company
BioMarin/Genzyme LLC

Completed

A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease

Mucopolysaccharidosis I | Scheie Syndrome | Hurler's Syndrome | Hurler-Scheie Syndrome

Brazil, Canada
Genzyme, a Sanofi Company
BioMarin/Genzyme LLC

Completed

Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I

Mucopolysaccharidosis I | Hurler-Scheie Syndrome | Hurlers Syndrome

United States, Canada, Germany
Genzyme, a Sanofi Company
BioMarin/Genzyme LLC

Completed

Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients

Mucopolysaccharidosis I | Scheie Syndrome | Hurler's Syndrome | Hurler-Scheie Syndrome

United States, Canada, United Kingdom, Brazil, Germany, Italy, Netherlands
Allergy Therapeutics

Completed

Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing

Type I Hypersensitivity

Canada
BioMarin Pharmaceutical

Terminated

Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome

Morquio A Syndrome | MPS IVA | Mucopolysaccharidosis IVA

United States, United Kingdom, Canada, Germany
Allergy Therapeutics

Withdrawn

Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen

Type I Hypersensitivity

Canada
BioMarin Pharmaceutical
ICON plc

Completed

A Multicenter, Multinational, Observational Morquio A Registry Study (MARS) (MARS)

Mucopolysaccharidosis IV Type A | Morquio A Syndrome | MPS IVA

United States, United Kingdom, Australia, Taiwan, Belgium, Malaysia, Austria, Canada, Portugal, France, Ireland, Czechia, Denmark, Italy, Netherlands, Poland, Puerto Rico
ZandA Technologies, llc
KGK Science Inc.

Completed

The Efficacy and Safety of an Amino Acid Supplement in Adults

Healthy | Insulin-Like Growth Factor I

Canada
BioMarin Pharmaceutical

Terminated

A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)

Morquio A Syndrome | MPS IV A | Mucopolysaccharidosis IVA

France, United Kingdom, Taiwan, United States, Argentina, Netherlands, Canada, Brazil, Germany, Italy
BioMarin Pharmaceutical

Completed

Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Morquio A Syndrome | MPS IVA | Mucopolysaccharidosis IV A

United States, Canada, France, Taiwan, Argentina, Colombia, Spain, Turkey, Japan, Saudi Arabia, Netherlands, Denmark, Korea, Republic of, Brazil, United Kingdom, Germany, Norway, Portugal, Italy, Qatar
Factors Group of Nutritional Companies Inc.
Isura

Completed

Metabolic Differences Between Dihydroberberine and Micellar Berberine

Phase I and Phase II Metabolites of Berberine

Canada
AbbVie

Recruiting

Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I Disorder (CReW BP-I)

Bipolar I Disorder

Canada
Allergy Therapeutics

Completed

Efficacy and Safety/Tolerability of Ragweed MATA MPL

Type I Hypersensitivity

Canada, United States
Shire

Terminated

Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric ENT Surgery (The HATT Project)

Mucopolysaccharidosis (MPS)

United States, Canada, United Kingdom, Turkey, Italy, Mexico, Spain
Allergy Therapeutics

Completed

Efficacy and Safety/Tolerability of Grass MATA MPL

Type I Hypersensitivity

United States, Canada, United Kingdom, Austria
Allergy Therapeutics

Completed

Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine

Type I Hypersensitivity

Canada
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder (ATLAS)

Bipolar I

United States, France, Romania, Poland, Canada, Hungary, Japan, Korea, Republic of, Malaysia, Taiwan
University of British Columbia

Completed

Lurasidone and Cognition in Bipolar I Disorder

Bipolar I Disorder

Canada
Allergy Therapeutics

Completed

Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Allergy

Type I Hypersensitivity

Canada
University of British Columbia
AstraZeneca; Ozmosis Research Inc.

Recruiting

SCION: SABR and Checkpoint Inhibition Of NSCLC (SCION)

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Lung Cancer Stage I | Lung Adenocarcinoma, Stage I | Lung Squamous Cell Carcinoma Stage I

Canada
University of British Columbia

Terminated

Treatment of Type I Supracondylar Fractures of the Humerus

Type I Supracondylar Fracture of the Humerus

Canada
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients

Bipolar I Disorder

United States, Taiwan, Romania, Korea, Republic of, Japan, Poland, Canada
Centre hospitalier de l'Université de Montréal...

Active, not recruiting

Outside the Cage (OTC) Robotic Lobectomy (OTC-RATS)

Lung Cancer Stage I

Canada
BioMarin Pharmaceutical

Completed

A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

MPS IV A

United States, Canada, France, United Kingdom, Taiwan, Argentina, Colombia, Japan, Saudi Arabia, Netherlands, Denmark, Korea, Republic of, Brazil, Germany, Portugal, Italy, Qatar
Centre hospitalier de l'Université de Montréal...
Maisonneuve-Rosemont Hospital

Recruiting

Corneal Collagen Crosslinking to Increase the Resistance of the Support Graft of the KPro Type I Against Corneal Melting (CXL-KPro)

Corneal Melting in Boston Keratoprosthesis Type I

Canada
Marie-Claude Robert
Fonds de recherche en ophtalmologie de l'Université de Montréal

Completed

Frozen Versus Fresh Corneal Carriers for the Boston KPro Type I Donor Carriers

Corneal Blindness | Boston Keratoprosthesis Type I Candidate

Canada
University of Alberta
Sernova Corp

Terminated

A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation

Type I Diabetes

Canada
Denali Therapeutics Inc.

Enrolling by invitation

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Mucopolysaccharidosis II

United States, Canada, Belgium, Czechia, Netherlands
Shire

Completed

Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase

Hunter Syndrome | Mucopolysaccharidosis II (MPS II)

United States, France, United Kingdom, Germany, Sweden, Spain, Brazil, Canada, Italy, Romania
Jayasree Basivireddy

Recruiting

Assessing the Role of Cariprazine in Improving Cognition in Euthymic Bipolar Patients (CARPZ-01)

Cognitive Impairment | Bipolar I Disorder

Canada
Novartis Pharmaceuticals

Terminated

Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.

Familial Chylomicronemia Syndrome (FCS) (HLP Type I)

South Africa, Germany, United Kingdom, France, United States, Canada, Netherlands
University of British Columbia
GlaxoSmithKline; Canadian Institutes of Health Research (CIHR); Lundbeck Canada... and other collaborators

Completed

Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.

Bipolar I Disorder

Canada
Denali Therapeutics Inc.

Recruiting

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II) (COMPASS)

Mucopolysaccharidosis II

United States, Spain, United Kingdom, Czechia, France, Canada, Italy, Belgium, Netherlands, Germany, Argentina, Sweden, Turkey, Colombia, Brazil
Amsterdam Molecular Therapeutics
ICON plc

Terminated

Duration of Effect of Alipogene Tiparvovec Treatment, Which Was Administered in Other Studies

Hyperlipoproteinemia Type I

Canada
Joshua Rosenblat

Recruiting

Ketamine for Treatment-Resistant Bipolar Disorder (KET-BD)

Bipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II Disorder

Canada
University of British Columbia
Eli Lilly and Company; Canadian Institutes of Health Research (CIHR); Janssen-Ortho...

Completed

Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode

Bipolar I Disorder

Canada
Université de Sherbrooke
Institut de Recherches Cliniques de Montreal

Recruiting

Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency (AGL12)

Lipoprotein Lipase Deficiency

Canada
University of Manitoba
Co-Investigator - Dr. Cheryl Rockman-Greenberg

Completed

Comparison of the Effect of a Novel Starch (Glycosade) Versus Gastrostomy Tube-Dextrose Infusion on Overnight Euglycaemia Control in Children With Glycogen Storage Disease Type I: Open Label Demonstration Trial (Glycosade GSD)

Hypoglycemia | Glycogen Storage Disorder Type 1 | Cornstarch | Glycosade

Canada
University Health Network, Toronto

Recruiting

Virtual Rehabilitation for Cancer Survivors

Lymphoma | Lymphoproliferative Disorders | Breast Cancer Stage I | Breast Cancer Stage II | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Breast Cancer Stage III | Colorectal Cancer Stage I | Head and Neck Cancer Stage III | Breast Cancer, Stage 0 | Head and Neck Cancer Stage I | Head and Neck Cancer...

Canada
Amsterdam Molecular Therapeutics
International Antiviral Therapy Evaluation Center

Unknown

Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X]

Familial Lipoprotein Lipase Deficiency

Canada
UniQure Biopharma B.V.
Chiesi Farmaceutici S.p.A.

Withdrawn

Alipogene Tiparvovec for the Treatment of LPLD Patients

LPL Deficiency

Canada, United States
Amsterdam Molecular Therapeutics
The Clinical Trial Company

Completed

Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects

Familial Lipoprotein Lipase Deficiency

Canada

Clinical Trials on Mucopolysaccharidosis Type I (MPS I) in Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations